-+ 0.00%
-+ 0.00%
-+ 0.00%

PARABILIS MEDICINES - INTENDS TO USE ABOUT $150 MLN OF IPO PROCEEDS TO CONTINUE ONGOING CLINICAL DEVELOPMENT OF ZOLUCATETIDE IN DESMOID TUMORS

Reuters·06/04/2026 10:18:14

Please log in to view news